Over-expression of MAGED4B increases cell migration and growth in oral squamous cell carcinoma and is associated with poor disease outcome

Cancer Letters

Volumn 321, Issue 1, 2012, Pages 18-26

  Chong, Chan Eng ^a   Lim, Kue Peng ^a   Gan, Chai Phei ^a   Marsh, Christina A ^b   Zain, Rosnah Binti ^c   Abraham, Mannil Thomas ^d   Prime, Stephen S ^e   Teo, Soo Hwang ^a   Silvio Gutkind, J ^b   Patel, Vyomesh ^b   Cheong, Sok Ching ^a,c  

^a CANCER RESEARCH INITIATIVES FOUNDATION   (Malaysia)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c UNIVERSITY OF MALAYA   (Malaysia)

^d Hospital Tengku Ampuan Rahimah   (Malaysia)

^e BRISTOL DENTAL HOSPITAL   (United Kingdom)

Author keywords

MAGED4B; Melanoma antigens; Migration; Oral Squamous Cell Carcinoma (OSCC)

Indexed keywords

CISPLATIN; MELANOMA ANTIGEN; MELANOMA ANTIGEN D4B; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER PROGNOSIS; CANCER SURVIVAL; CARCINOGENESIS; CELL CYCLE; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISEASE SPECIFIC SURVIVAL; DRUG RESISTANCE; DRUG SENSITIVITY; FEMALE; GENE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE METASTASIS; MALE; MELANOMA ANTIGEN D4B GENE; MOUSE; MOUTH SQUAMOUS CELL CARCINOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOSENSITIVITY;

AGED; ANTIGENS, NEOPLASM; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MOUTH NEOPLASMS; PROGNOSIS; RADIATION TOLERANCE; UP-REGULATION;

EID: 84860343616     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.03.025     Document Type: Article

References (51)

1. de Camargo Cancela M., Chapuis F., Curado M.P. Abstracting stage in population-based cancer registries: the example of oral cavity and oropharynx cancers. Cancer Epidemiol. 2010, 34:501-506.
2. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN. Int. J. Cancer 2008, 127(2010):2893-2917.
3. Jemal A., Clegg L.X., Ward E., Ries L.A., Wu X., Jamison P.M., Wingo P.A., Howe H.L., Anderson R.N., Edwards B.K. Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. Cancer 2004, 101:3-27.
4. Mork J. Forty years of monitoring head and neck cancer in Norway - no good news. Anticancer Res. 1998, 18:3705-3708.
5. Vermorken J.B., Mesia R., Rivera F., Remenar E., Kawecki A., Rottey S., Erfan J., Zabolotnyy D., Kienzer H.R., Cupissol D., Peyrade F., Benasso M., Vynnychenko I., De Raucourt D., Bokemeyer C., Schueler A., Amellal N., Hitt R. Platinum-based chemotherapy plus cetuximab in head and neck cancer. New Engl. J. Med. 2008, 359:1116-1127.
6. De Plaen E., Arden K., Traversari C., Gaforio J.J., Szikora J.P., De Smet C., Brasseur F., van der Bruggen P., Lethe B., Lurquin C., et al. Structure, chromosomal localization, and expression of 12 genes of the MAGE family. Immunogenetics 1994, 40:360-369.
7. Jungbluth A.A., Stockert E., Chen Y.T., Kolb D., Iversen K., Coplan K., Williamson B., Altorki N., Busam K.J., Old L.J. Monoclonal antibody MA454 reveals a heterogeneous expression pattern of MAGE-1 antigen in formalin-fixed paraffin embedded lung tumours. Br. J. Cancer 2000, 83:493-497.
8. Osterlund C., Tohonen V., Forslund K.O., Nordqvist K. Mage-b4, a novel melanoma antigen (MAGE) gene specifically expressed during germ cell differentiation. Cancer Res. 2000, 60:1054-1061.
9. van der Bruggen P., Traversari C., Chomez P., Lurquin C., De Plaen E., Van den Eynde B., Knuth A., Boon T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991, 254:1643-1647.
10. Marchand M., van Baren N., Weynants P., Brichard V., Dreno B., Tessier M.H., Rankin E., Parmiani G., Arienti F., Humblet Y., Bourlond A., Vanwijck R., Lienard D., Beauduin M., Dietrich P.Y., Russo V., Kerger J., Masucci G., Jager E., De Greve J., Atzpodien J., Brasseur F., Coulie P.G., van der Bruggen P., Boon T. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int. J. Cancer 1999, 80:219-230.
11. Marchand M., Weynants P., Rankin E., Arienti F., Belli F., Parmiani G., Cascinelli N., Bourlond A., Vanwijck R., Humblet Y., et al. Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int. J. Cancer 1995, 63:883-885.
12. Mukherji B., Chakraborty N.G., Yamasaki S., Okino T., Yamase H., Sporn J.R., Kurtzman S.K., Ergin M.T., Ozols J., Meehan J., et al. Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. Proc. Natl. Acad. Sci. USA 1995, 92:8078-8082.
13. Barker P.A., Salehi A. The MAGE proteins: emerging roles in cell cycle progression, apoptosis, and neurogenetic disease. J. Neurosci. Res. 2002, 67:705-712.
14. Simpson A.J., Caballero O.L., Jungbluth A., Chen Y.T., Old L.J. Cancer/testis antigens, gametogenesis and cancer. Nat. Rev. Cancer 2005, 5:615-625.
15. Chomez P., De Backer O., Bertrand M., De Plaen E., Boon T., Lucas S. An overview of the MAGE gene family with the identification of all human members of the family. Cancer Res. 2001, 61:5544-5551.
16. Xiao J., Chen H.S. Biological functions of melanoma-associated antigens. World J. Gastroenterol. 2004, 10:1849-1853.
17. Cheong S.C., Chandramouli G.V., Saleh A., Zain R.B., Lau S.H., Sivakumaren S., Pathmanathan R., Prime S.S., Teo S.H., Patel V., Gutkind J.S. Gene expression in human oral squamous cell carcinoma is influenced by risk factor exposure. Oral Oncol. 2009, 45:712-719.
18. Germano S., Kennedy S., Rani S., Gleeson G., Clynes M., Doolan P., McDonnell S., Hughes L., Crown J., O'Driscoll L. MAGE-D4B is a novel marker of poor prognosis and potential therapeutic target involved in breast cancer tumorigenesis. Int. J. Cancer 2011.
19. Lucas S., Brasseur F., Boon T. A new MAGE gene with ubiquitous expression does not code for known MAGE antigens recognized by T cells. Cancer Res. 1999, 59:4100-4103.
20. Pold M., Zhou J., Chen G.L., Hall J.M., Vescio R.A., Berenson J.R. Identification of a new, unorthodox member of the MAGE gene family. Genomics 1999, 59:161-167.
21. Glazer C.A., Smith I.M., Bhan S., Sun W., Chang S.S., Pattani K.M., Westra W., Khan Z., Califano J.A. The role of MAGEA2 in head and neck cancer. Arch. Otolaryngol. Head Neck Surg. 2011, 137:286-293.
22. Ito S., Kawano Y., Katakura H., Takenaka K., Adachi M., Sasaki M., Shimizu K., Ikenaka K., Wada H., Tanaka F. Expression of MAGE-D4, a novel MAGE family antigen, is correlated with tumor-cell proliferation of non-small cell lung cancer. Lung cancer 2006, 51:79-88.
23. Jang S.J., Soria J.C., Wang L., Hassan K.A., Morice R.C., Walsh G.L., Hong W.K., Mao L. Activation of melanoma antigen tumor antigens occurs early in lung carcinogenesis. Cancer Res. 2001, 61:7959-7963.
24. Mollaoglu N., Vairaktaris E., Nkenke E., Neukam F.W., Ries J. Expression of MAGE-A12 in oral squamous cell carcinoma. Dis. Markers 2008, 24:27-32.
25. Ries J., Vairaktaris E., Mollaoglu N., Wiltfang J., Neukam F.W., Nkenke E. Expression of melanoma-associated antigens in oral squamous cell carcinoma. J. Oral Pathol. Med. 2008, 37:88-93.
26. Sasaki M., Nakahira K., Kawano Y., Katakura H., Yoshimine T., Shimizu K., Kim S.U., Ikenaka K. MAGE-E1, a new member of the melanoma-associated antigen gene family and its expression in human glioma. Cancer Res. 2001, 61:4809-4814.
27. Tsai J.R., Chong I.W., Chen Y.H., Yang M.J., Sheu C.C., Chang H.C., Hwang J.J., Hung J.Y., Lin S.R. Differential expression profile of MAGE family in non-small-cell lung cancer. Lung cancer 2007, 56:185-192.
28. Doyle J.M., Gao J., Wang J., Yang M., Potts P.R. MAGE-ING protein complexes comprise a family of E3 ubiquitin ligases. Mol. Cell 2010, 39:963-974.
29. Feng Y., Gao J., Yang M. When MAGE meets RING: insights into biological functions of MAGE proteins. Protein Cell 2011, 2:7-12.
30. Nardiello T., Jungbluth A.A., Mei A., Diliberto M., Huang X., Dabrowski A., Andrade V.C., Wasserstrum R., Ely S., Niesvizky R., Pearse R., Coleman M., Jayabalan D.S., Bhardwaj N., Old L.J., Chen-Kiang S., Cho H.J. MAGE-A inhibits apoptosis in proliferating myeloma cells through repression of Bax and maintenance of survivin. Clin. Cancer Res. 2011, 17:4309-4319.
31. Yang B., O'Herrin S.M., Wu J., Reagan-Shaw S., Ma Y., Bhat K.M., Gravekamp C., Setaluri V., Peters N., Hoffmann F.M., Peng H., Ivanov A.V., Simpson A.J., Longley B.J. MAGE-A, mMage-b, and MAGE-C proteins form complexes with KAP1 and suppress p53-dependent apoptosis in MAGE-positive cell lines. Cancer Res. 2007, 67:9954-9962.
32. Ogata K., Aihara R., Mochiki E., Ogawa A., Yanai M., Toyomasu Y., Ando H., Ohno T., Asao T., Kuwano H. Clinical significance of melanoma antigen-encoding gene-1 (MAGE-1) expression and its correlation with poor prognosis in differentiated advanced gastric cancer. Ann. Surg. Oncol. 2011, 18:1195-1203.
33. Jordan B.W., Dinev D., LeMellay V., Troppmair J., Gotz R., Wixler L., Sendtner M., Ludwig S., Rapp U.R. Neurotrophin receptor-interacting mage homologue is an inducible inhibitor of apoptosis protein-interacting protein that augments cell death. J. Biol. Chem. 2001, 276:39985-39989.
34. Reddy E.M., Chettiar S.T., Kaur N., Ganeshkumar R., Shepal V., Shanbhag N.C., Shiras A. Dlxin-1, a member of MAGE family, inhibits cell proliferation, invasion and tumorigenicity of glioma stem cells. Cancer Gene Ther. 2011, 18:206-218.
35. Taniura H., Matsumoto K., Yoshikawa K. Physical and functional interactions of neuronal growth suppressor necdin with p53. J. Biol. Chem. 1999, 274:16242-16248.
36. Wan D., Gong Y., Qin W., Zhang P., Li J., Wei L., Zhou X., Li H., Qiu X., Zhong F., He L., Yu J., Yao G., Jiang H., Qian L., Yu Y., Shu H., Chen X., Xu H., Guo M., Pan Z., Chen Y., Ge C., Yang S., Gu J. Large-scale cDNA transfection screening for genes related to cancer development and progression. Proc. Natl. Acad. Sci. USA 2004, 101:15724-15729.
37. *25-restricted MHC class I ligand from solid tumor tissue. Cancer Biol. Ther. 2005, 4:943-948.
38. Germano S., Kennedy S., Rani S., Gleeson G., Clynes M., Doolan P., McDonnell S., Hughes L., Crown J., O'Driscoll L. MAGE-D4B is a novel marker of poor prognosis and potential therapeutic target involved in breast cancer tumorigenesis. Int. J. Cancer 2011.
39. Hamid S., Lim K.P., Zain R.B., Ismail S.M., Lau S.H., Mustafa W.M., Abraham M.T., Nam N.A., Teo S.H., Cheong S.C. Establishment and characterization of Asian oral cancer cell lines as in vitro models to study a disease prevalent in Asia. Int. J. Mol. Med. 2007, 19:453-460.
40. Saleh A., Zain R.B., Hussaini H., Ng F., Tanavde V., Hamid S., Chow A.T., Lim G.S., Abraham M.T., Teo S.H., Cheong S.C. Transcriptional profiling of oral squamous cell carcinoma using formalin-fixed paraffin-embedded samples. Oral Oncol. 2010, 46:379-386.
41. Valster A., Tran N.L., Nakada M., Berens M.E., Chan A.Y., Symons M. Cell migration and invasion assays. Methods 2005, 37:208-215.
42. Geback T., Schulz M.M., Koumoutsakos P., Detmar M. TScratch: a novel and simple software tool for automated analysis of monolayer wound healing assays. Biotechniques 2009, 46:265-274.
43. Nystrom M.L., Thomas G.J., Stone M., Mackenzie I.C., Hart I.R., Marshall J.F. Development of a quantitative method to analyse tumour cell invasion in organotypic culture. J. Pathol. 2005, 205:468-475.
44. Gaggioli C., Hooper S., Hidalgo-Carcedo C., Grosse R., Marshall J.F., Harrington K., Sahai E. Fibroblast-led collective invasion of carcinoma cells with differing roles for RhoGTPases in leading and following cells. Nat. Cell Biol. 2007, 9:1392-1400.
45. Chin L., Gray J.W. Translating insights from the cancer genome into clinical practice. Nature 2008, 452:553-563.
46. Monte M., Simonatto M., Peche L.Y., Bublik D.R., Gobessi S., Pierotti M.A., Rodolfo M., Schneider C. MAGE-A tumor antigens target p53 transactivation function through histone deacetylase recruitment and confer resistance to chemotherapeutic agents. Proc. Natl. Acad. Sci. USA 2006, 103:11160-11165.
47. Wang C., Ivanov A., Chen L., Fredericks W.J., Seto E., Rauscher F.J., Chen J. MDM2 interaction with nuclear corepressor KAP1 contributes to p53 inactivation. EMBO J. 2005, 24:3279-3290.
48. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
49. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
50. Ridley A.J. Rho GTPases and cell migration. J. Cell Sci. 2001, 114:2713-2722.
51. Schmitz A.A., Govek E.E., Bottner B., Van Aelst L. Rho GTPases: signaling, migration, and invasion. Exp. Cell Res. 2000, 261:1-12.